Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers

    July 2016 in “ Experimental Dermatology
    Ali Jabbari, Nhan Nguyen, Jane Cerise, Grace Ulerio, Annemieke de Jong, Raphael Clynes, Angela M. Christiano, Julian Mackay‐Wiggan
    Image of study
    TLDR A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
    In a study published on July 27, 2016, a 40-year-old Caucasian woman with moderate to severe alopecia areata (AA) experienced significant hair regrowth after treatment with tofacitinib, a Janus kinase inhibitor. The patient, who had a history of AA that temporarily resolved during pregnancy but recurred postpartum, had previously seen limited benefits from conventional treatments. Upon enrolling in an open-label pilot study, she began taking tofacitinib 5 mg twice daily. Within one month, patchy hair regrowth was observed, and by three months, she had 94% scalp hair regrowth, with significant regrowth of eyebrows and eyelashes as well. No adverse events or laboratory abnormalities were reported. However, cessation of tofacitinib led to near-complete hair loss. Skin biopsies and blood draws before and after four weeks of treatment showed decreased serum levels of CXCL10, an interferon-induced chemokine, and a reduction in the AA Disease Activity Index (ALADIN) profile, indicating a decrease in interferon and cytotoxic T lymphocyte signatures. These results suggest that tofacitinib is a promising treatment for AA, but larger clinical studies are needed to assess safety, efficacy, and the durability of the treatment, as well as to correlate biomarkers with response.
    View this study on →

    Cited in this study

    5 / NoResults